Investigators Pause Trial for MGTA-117 in Relapsed/Refractory AML and MDS
January 30, 2023

Investigators say that a phase 1/2 trial evaluating MGTA-117 in 2 hematologic malignancies has been paused following a serious adverse effect that may be related to the agent.

Kevin Kalinsky, MD, MS, Discusses the Past, Present, and Future of Breast Cancer Research
January 30, 2023

“Nonetheless, we saw tremendous benefits for these patients, patients who didn’t benefit from other treatments, and it was exciting to be involved with this early research.”

Expert Details ‘Exciting’ Bispecific Combos for Lymphoma
January 30, 2023

Combining bispecific antibodies with other agents such as R-CHOP and R-CHP for various subtypes of lymphoma has the potential to produce exciting results, according to an expert from Dana-Farber Cancer Institute.

Progressing From Disparity to Equity: Untangling the Complexities of Timely Care and the Rural Cancer Experience
January 29, 2023

Richard L. Martin III, MD, MPH, and Stephen Schleicher, MD, MBA, share a perspective on rural cancer care.

Artificial Intelligence May Help Oncologists Better Risk-Stratify Patients With Prostate Cancer
January 29, 2023

Early study results show that an artificial intelligence model may help oncologists better stratify patients with prostate cancer into risk groups than existing methods, according to an expert.

Radiation Shown to Improve Survival in Liver Cancer ‘For the First Time’
January 28, 2023

Adding radiation to sorafenib elicited a survival improvement in a group of patients with hepatocellular carcinoma, a type of liver cancer.

Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic Factors
January 28, 2023

Minh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer.

FDA Grants Approval to Elacestrant for ER+/HER2– Advanced Metastatic Breast Cancer
January 27, 2023

Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer can now receive elacestrant as treatment following the FDA’s approval of the agent.

HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care
January 27, 2023

Closing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.